Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?

Eur J Health Econ. 2015 May;16(4):341-5. doi: 10.1007/s10198-014-0653-x.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / economics*
  • Antiviral Agents / therapeutic use
  • Cost-Benefit Analysis
  • Drug Costs*
  • Europe
  • Health Policy / economics
  • Hepatitis C / drug therapy
  • Hepatitis C / economics*
  • Humans

Substances

  • Antiviral Agents